Nouscom

Nouscom is a private clinical stage immuno-oncology company developing off-the-shelf and personalized cancer immunotherapies using proprietary viral vectors with demonstrated high immunogenicity in patients. Nouscom’s clinical pipeline includes NOUS-209, an off-the-shelf cancer immunotherapy assessing the efficacy of the treatment in advanced MSI-H CRC patients in combination with pembrolizumab in randomized phase 2 trials. A Phase 1b study of NOUS-209 monotherapy in Lynch Syndrome Carriers with potential to ‘intercept cancer’ before it occurs is running in collaboration with the National Cancer Institute. Nouscom's second clinical program is NOUS-PEV, a personalized cancer immunotherapy for the treatment of advanced cancers with great unmet medical need. Nouscom has exclusively out-licensed VAC-85135, an off-the-shelf immunotherapy, to Janssen Oncology. The program is under evaluation in a Phase 1 trial for the treatment of Myeloproliferative Neoplasms. Nouscom was founded in 2015 and is headquartered in Basel, Switzerland with operations in Rome, Italy. The company is backed by international life sciences investors: 5AM, Andera Partners, Bpifrance, EQT Life Sciences, Indaco Venture Partners, M Ventures, Panakes Partners, Revelation Partners, Versant Ventures, and XGen Ventures and has raised a total of $130M to date. For more information on Nouscom, please visit the company’s website at www.nouscom.com